Top

Quality of Life Research

Published in:

Open Access 01-09-2020 | Atopic Dermatitis

Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study

Authors: Andreas Westh Vilsbøll, Nana Kragh, Julie Hahn-Pedersen, Cathrine Elgaard Jensen

Published in: Quality of Life Research | Issue 9/2020

Abstract

Purpose

To develop a mapping algorithm for generating EQ-5D-5-level (EQ-5D-5L) utility scores from the Dermatology Life Quality Index (DLQI) in patients with atopic dermatitis (AD).

Methods

The algorithm was developed using data from 1232 patients from four countries participating in the National Health and Wellness Study. Spearman’s rank correlation coefficient was used to evaluate the conceptual overlap between DLQI and EQ-5D-5L. Six mapping models (ordinary least squares [OLS], Tobit, three different two-part models, and a regression mixture model) were tested with different specifications to determine model performance and were ranked based on the sum of mean absolute error (MAE), and root mean squared error (RMSE).

Results

The mean DLQI score was 7.23; mean EQ-5D-5L score was 0.78; and there were moderate negative correlations between DLQI and EQ-5D-5L scores (p = − 0.514). A regression mixture model with total DLQI, and age and sex as independent variables performed best for mapping DLQI to EQ-5D-5L (RMSE = 0.113; MAE = 0.079).

Conclusion

This was the first study to map DLQI to EQ-5D-5L exclusively in patients with AD. The regression mixture model with total DLQI, and age and sex as independent variables was the best performing model and accurately predicted EQ-5D-5L. The results of this mapping can be used to translate DLQI data from clinical studies to health state utility values in economic evaluations.

Available only for authorised users

Barbarot, S., Auziere, S., Gadkari, A., Girolomoni, G., Puig, L., Simpson, E., et al. (2018). Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy, 73(6), 1284–1293. https://doi.org/10.1111/all.13401.PubMedCrossRef

Weidinger, S., & Novak, N. (2016). Atopic dermatitis. Lancet, 387, 1109–1122.PubMedCrossRef

The Economist Intelligence Unit. (2018). A misunderstood skin disease: Mapping the policy response to atopic dermatitis. Retrieved July 3, 2019 from https://eiuperspectives.economist.com/sites/default/files/A%20misunderstood%20skin%20disease_Mapping%20the%20policy%20response%20to%20atopic%20dermatitis.pdf.

Chalmers, J., Thomas, K., Apfelbacher, C., Williams, H., Prinsen, C., Spuls, P., et al. (2018). Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). BJD, 178, e332–2341.CrossRef

NICE. (2019). Position statement on use of the EQ-5D-5L value set for England (updated October 2019). Retrieved Feburary 3, 2020 from https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l.

Canadian Agency for Drugs and Technologies in Health. (2017). Guidelines for the Economic Evaluation of Health Technologies. Retrieved November 20, 2018 from https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf.

Heinl, D., Chalmers, J., Nankervis, H., & Apfelbacher, C. (2016). Quality of life instruments used and their relation to patient-reported outcomes: A systematic review. Acta Dermato Venereology, 96(5), 596–605.CrossRef

Basra, M., Fenech, R., Gatt, R., Salek, M., & Finlay, A. (2008). The Dermatology Life Quality Index 1994–2007: A comprehensive review of validation data and clinical results. BJD, 159, 997–1035.

Cardiff University. (2018). Dermatology Quality Life Index (DLQI). Retrieved November 20, 2018 from https://sites.cardiff.ac.uk/dermatology/quality-oflife/dermatology-quality-of-life-index-dlqi/.

10.

Finlay, A., & Khan, G. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.PubMedCrossRef

11.

Versteegh, M., Leunis, A., Uyl-de Groot, C., & Stolk, E. (2012). Condition-specific preference-based measures: Benefit or burden? Value in Health, 15, 504–513.PubMedCrossRef

12.

Rowen, D., Brazier, J., Ara, R., & Zouraq, I. (2017). The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics, 35(Suppl 1), S33–S41.CrossRef

13.

Davison, N., Thompson, A., Turner, A., Longworth, L., McElhone, K., Griffiths, C., et al. (2018). Generating EQ-5D-3L utility scores from the Dermatology Life Quality Index: A mapping study in patients with psoriasis. Value in Health, 21, 1010–1018.PubMedCrossRef

14.

NICE. (2013). Guide to the methods of technology appraisal 2013. Retrieved November 20, 2018 from https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.

15.

Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., et al. (2015). The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: Explanation and elaboration. PharmacoEconomics, 33, 993–1011.PubMedCrossRef

16.

EuroQoL. (2018). EuroQoL instruments. Retrieved November 20, 2018 from https://euroqol.org/eq-5d-instruments/.

17.

Longworth, L., & Rowen, D. (2013). Mapping to Obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health, 16, 202–210.PubMedCrossRef

18.

Bucholz, I., Janssen, M., Kohlman, T., & Feng, Y. (2018). A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. PharmacoEconomics, 36, 645–661.CrossRef

19.

Longworth, L., & Rowen, D. (2011). NICE DSU technical support document 10: The use of mapping methods to estimate health state utility values. Retrieved November 20, 2018 from https://www.nicedsu.org.uk.

20.

Wailoo, A., Hernandez-Alava, M., Manca, A., Meija, A., Ray, J., Crawford, B., et al. (2017). Mapping to Estimate health-state utility from non-preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value in Health, 20, 18–27.PubMedCrossRef

21.

Kantar Health. (2016). National Health and Wellness Survey. Retrieved November 20, 2018 from www.kantarhealth.com.

22.

Health Economics (2017). National Health and Wellness Survey. Retrieved December 5, 2018 from https://www.healtheconomics.com/resource/national-health-and-wellnesssurvey.

23.

Nyberg, F. (2017). Observational study report characterization of moderate-severe atopic dermatitis disease severity and burden in moderate-to-severe AD. A non-interventional cross-sectional burden of disease study among adults with AD in France, Germany, UK, and USA.

24.

Nyberg, F., Varol, N., & Hansen, J. (2017). Greater severity of atopic dermatitis is associated with poorer patient-reported outcomes among adults with moderate-to-severe atopic dermatitis. Paper presented at the The European Academy of Dermatology and Venereology (EADV) Congress, Geneva, Switzerland, September 13–17, 2017

25.

World Medical Association (2018, July 9th). WMA declaration of Helsinki: Ethical principles for medical research involving human subjects. Retrieved February 5, 2018 from https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.

26.

International Council for Harmonization (ICH) (1996). ICH Harmonised Tripartite Guideline. Retrieved February 14, 2019 from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed Feb 14 2019.

27.

Altpeter, E., Burnand, B., Capkun, G., et al. (2005). Essentials of good epidemiological practice. Sozial- und Praventivmedizin, 50, 12–27.PubMedCrossRef

28.

van Reenen, M., & Janssen, B. (2015). EQ-5D-5L User Guide: Basic information on how to use the EQ-5D-5L instrument. (Version 2.1 ed.).

29.

van Reenen, M., & Oppe, M. (2015). EQ-5D-3L User Guide: Basic information on how to use the EQ-5D-3L instrument. (Version 5.1 ed.).

30.

Devlin, N., Shah, K., Feng, Y., Mulhern, B., & van Hout, B. (2017). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 1, 16.

31.

EuroQoL. (2017). EQ-5D-5L/About. Retrieved July 3, 2019 from https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/. Accessed July 3 2019.

32.

Van Hout, B., Janssen, M., Feng, Y., Kohlman, T., Busschback, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 15, 708–715.PubMedCrossRef

33.

BMJ. (2018). 11. Correlation and regression. Retrieved November 20, 2018 from https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regression.

34.

Brazier, J., Yang, Y., Tsuchiya, A., & Rowen, D. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. European Journal of Health Economics, 11(2), 215–225.PubMedCrossRef

35.

Rowen, D., Brazier, J., & Roberts, J. (2009). Mapping SF-36 onto the EQ-5D index: How reliable is the relationship. Health and Quality of Life Outcomes, 7, 1–9.CrossRef

36.

Hernández Alava, M., Wailoo, A., & Ara, R. (2012). Tails from the peak district: Adjusted limited Dependent Variable Mixture Models of EQ-5D questionnaire health state utility values. Value in Health, 15, 550–561.PubMedCrossRef

37.

Mueller, S. (2019). Mixture Modeling: Mixture of Regressions. Retrieved December 5, 2019 from https://pages.mtu.edu/~shanem/psy5220/daily/Day19/Mixture_of_regressions.html.

38.

Lamont, A., Vermunt, J. K., & Van Horn, M. L. (2016). Regression mixture models: Does modeling the covariance between independent variables and latent classes improve the results? Multivariate Behave Research, 51(1), 35–52. https://doi.org/10.1080/00273171.2015.1095063.CrossRef

39.

Dempster, A., Laird, N., & Rubin, D. (1977). Maximum likelihood from incomplete data via the EM algorithm. Journal of the Royal Statistical Society, 39(1), 1–38.

40.

Chai, T., & Draxler, R. (2014). Root mean square error (RMSE) or mean absolute error (MAE)? Arguments against avoiding RMSE in the literature. Geosci Model Dev, 7, 1247–1250.CrossRef

41.

Team, R. C. (2008). R: A language and environment for statistical computing.

42.

Grün, B., & Leisch, F. (2008). FlexMix Version 2: Finite mixtures with concomitant variables and varying and constant parameters. Journal of Statistical Software, 28(4), 1–35.CrossRef

43.

Blome, C., Beikert, F., & Rustenbach, S. (2013). Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Archives of Dermatological Research, 305, 197–204.PubMedCrossRef

44.

Currie, C., & Conway, P. (2007). PSK11: Evaluation of the association between EQ-5D utlity and dermatology life quality index (DLQI) score in patients with psoriasis. Value in Health, 10, A470–471.CrossRef

45.

Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mappi EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. European Journal Health of Economic, 1, S111–119.CrossRef

46.

Norlin, J., Steen, C., Persson, U., & Schmitt-Egenolf, M. (2012). Analysis of three outcome measures in moderate to severe psoriasis: A registry-based study of 2450 patients. British Journal of Dermatology, 166(4), 797–802.PubMedCrossRef

47.

Ali, F., Kay, R., Finlay, A., Piguet, V., Kupfer, J., Dalgard, F., et al. (2017). Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Quality of Life Research, 26, 3025–3034.PubMedPubMedCentralCrossRef

48.

Tennvall, G., Norlin, J., Malmberg, I., Erlendsson, A., & Haedersdal, M. (2015). Health related quality of life in patients with actinic keratosis: an observational study of patients treated in dermatology specialist care in Denmark. Health and Quality of Life Outcomes, 13, 111. https://doi.org/10.1186/s12955-015-0295-4.PubMedPubMedCentralCrossRef

49.

Paller, A., Jaworski, J., Simpson, E., Boguniewics, M., Russel, J., Block, J., et al. (2018). Major comorbidities of atopic dermatitis: Beyond allergic disorders. American Journal of Clinical Dermatology, 19(6), 821–838.PubMedCrossRef

50.

Brunner, P., Silverberg, J., Guttman-Yasky, E., Paller, A., Kabashima, K., & Amagai, M. (2017). Increasing comorbidities suggests that atopic dermatitis is a systemic disorder. Journal of Investigative Dermatology, 137, 18–25.PubMedCrossRef

51.

Bryman, A., & Bell, E. (2014). Business research methods. Retrieved May 22, 2018 from https://books.google.dk/books/about/Business_Research_Methods.html?id=l7u6BwAAQBAJ&redir_esc=y.

52.

Van Horn, M., Smith, J., Fagan, A., et al. (2012). Not quite normal: Consequences of violating the assumption of normality in regression mixture models. Struct Equ Modeling, 19(2), 227–249. https://doi.org/10.1080/10705511.2012.659622.CrossRef

53.

ClinicalTrials.gov. (2019). Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. Retrieved July 19, 2019 from https://clinicaltrials.gov/ct2/show/NCT03725722?term=delgocitinib&cond=atopic+dermatitis&rank=1.

54.

Wee, H., Yeo, K., Chong, K., et al. (2018). Mean rank, equipercentile, and regression mapping of world health organization quality of life brief (WHOQOL-BREF) to EuroQoL 5 dimensions 5 levels (EQ-5D-5L) utilities. Medical Decision Making, 38(3), 319–333. https://doi.org/10.1177/0272989X18756890.PubMedCrossRef

Title: Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study
Authors: Andreas Westh Vilsbøll
Nana Kragh
Julie Hahn-Pedersen
Cathrine Elgaard Jensen
Publication date: 01-09-2020
Publisher: Springer International Publishing
Keyword: Atopic Dermatitis
Published in: Quality of Life Research / Issue 9/2020
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-020-02499-1

At a glance: The STEP trials

Springer Medicine

Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2020

Patient-reported outcomes in maintenance hemodialysis: a cross-sectional, multicenter study

The association of socio-economic status, dental anxiety, and behavioral and clinical variables with adolescents’ oral health-related quality of life

Development of algorithms to estimate EQ-5D and derive health utilities from WHOQOL-HIV Bref: a mapping study

Nonrestorative sleep scale: a reliable and valid short form of the traditional Chinese version

Humour and laughing in patients with prolonged incurable cancer: an ethnographic study in a comprehensive cancer centre

Developmental differences in health-related quality of life in adolescent and young adult cancer survivors